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Abstract 40 
 Evidence generated from randomized controlled trials forms the foundation of 41 
cardiovascular therapeutics and has led to the adoption of numerous drugs and devices that 42 
prolong survival and reduce morbidity, as well as the avoidance of interventions that have been 43 
shown to be ineffective or even unsafe. Many aspects of cardiovascular research have evolved 44 
considerably since the first randomized trials in cardiology were conducted. In order to be large 45 
enough to provide reliable evidence about effects on major outcomes, cardiovascular trials may 46 
now involve thousands of patients recruited from hundreds of clinical sites in many different 47 
countries. Costly infrastructure has developed to meet the increasingly complex organizational 48 
and operational requirements of these clinical trials. Concerns have been raised that this 49 
approach is unsustainable, inhibiting the reliable evaluation of new and existing treatments, to 50 
the detriment of patient care. These issues were considered by patients, regulators, funders, and 51 
trialists at a meeting of the European Society of Cardiology Cardiovascular Roundtable in 52 
October 2015. This paper summarizes the key insights and discussions from the workshop, 53 
highlights subsequent progress, and identifies next steps to produce meaningful change in the 54 
conduct of cardiovascular clinical research. 55 
 56 
Key Words: clinical trials as topic; pragmatic clinical trials as topic; randomized controlled 57 
trials as topic; cardiovascular diseases  58 
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Introduction 59 
 Randomized controlled trials generate evidence on the benefits and harms of therapeutic 60 
interventions. Regulations and guidelines that govern clinical trials are intended to protect the 61 
rights, safety and wellbeing of the study participants and to provide assurance that the evidence 62 
generated can be relied on for individual patient care and the broader public health. However, 63 
there are concerns that these objectives are not being met due to significant problems with the 64 
interpretation and implementation of current regulations and guidelines.1-5 Moreover, the over-65 
interpretation of research governance requirements has inhibited methodological and 66 
technological innovation that could enhance the quality of cardiovascular trials. Moulding 67 
research to fit existing rules may not always be appropriate; instead regulations need to be 68 
flexible and allow proportionate approaches for each trial.6;7  69 
 The Cardiovascular Round Table of the European Society of Cardiology (ESC) convened 70 
a workshop to engender dialogue about improving the regulation and governance of clinical 71 
trials. Representatives from groups interested in clinical cardiovascular research (including 72 
patients, clinicians, regulators, funders, and trialists) collaborated to generate recommendations 73 
for optimal research and regulatory methods that would support rapid, reliable, and cost-effective 74 
evidence generation, while protecting the safety of clinical trial participants (see Figure 1).  75 
 76 
Research Governance Challenges Facing Clinical Trials 77 
 The International Council for (formerly Conference on) Harmonisation of Technical 78 
Requirements for Registration of Pharmaceuticals for Human Use Good Clinical Practice E6 79 
(ICH-GCP) guideline was finalised in 1996 and has become established as the standard for the 80 
conduct of clinical trials worldwide.8 Developed by a select group of regulatory authorities and 81 
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organizations representing the pharmaceutical industry (but without any input from non-82 
commercial trialists or patient advocates), it was intended to provide consistency in the 83 
requirements for clinical trials conducted to support regulatory evaluations of new drugs across 84 
multiple countries. The guideline was not aimed at other types of clinical trials, such as non-85 
registration trials, non-interventional studies, or trials of non-pharmacological interventions. 86 
However, it has been applied and, indeed, even mandated well beyond its original remit. For 87 
example, the European Union’s (EU) new Clinical Trials Regulation requires that trial sponsors 88 
and investigators take account of ICH-GCP in all clinical trials of any medicinal product.9  89 
Similarly, the Gates Foundation requires grantees to adhere to ICH-GCP, even when they are 90 
conducting clinical trials in resource poor settings that are not intended for registration.10  91 
Recently, ICH has acknowledged some of the problems with the GCP guideline11 and 92 
initiated a public consultation on an E6 (R2) integrated addendum in 2015. Following comments 93 
from ESC and many other organizations interested in clinical trials,12 ICH released a modified 94 
version in November 2016 for adoption and implementation.13 However, concerns remain that 95 
this revision does not address fundamental problems with the ICH-GCP guideline and does not 96 
correct errors and inconsistencies in the original text (see Table 1).14-16  ICH has also announced 97 
its intention to conduct a more substantial overhaul of guidelines that relate to GCP and clinical 98 
trial design, and have promised to publish a reflection paper outlining their plans in early 2017.17 99 
Greater emphasis on the key scientific principles (e.g., maintaining the integrity of the 100 
randomization process, adherence to allocated study treatment, minimizing losses to follow-up) 101 
would have a greater impact on the quality of trial results than is achieved by the current focus 102 
on documentation and data checking in ICH-GCP,15;16 but these aspects are not included in the 103 
proposed revisions and are not a focus of GCP inspections by regulators.18 This failure can have 104 
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serious detrimental effects; for example, it was found that researchers did not consider it to be 105 
critical to minimize losses to follow-up after randomization (which allows unbiased “intention-106 
to-treat” treatment comparisons) because it is not emphasized in ICH-GCP or included in ICH-107 
GCP training.15  108 
 109 
Quality Assurance and Risk-based Monitoring 110 
 The ICH-GCP guideline is intended to ensure the credibility of clinical trial results. For 111 
example, it states that those responsible for the trial (i.e., the regulatory “sponsor”; which is not 112 
necessarily the funder) should “ensure that trials are adequately monitored” and “determine the 113 
appropriate extent and nature of monitoring”, and it emphasizes that “in general there is a need 114 
for on-site monitoring”.8 These statements have been over-interpreted;18 consequently, site-based 115 
monitoring with extensive checking of source documentation is the prevailing method used in 116 
many trials and by many regulatory inspectors.18;19 On-site monitoring is amongst the most 117 
costly operational activities in a clinical trial,20 and there are serious concerns about its ability to 118 
detect important errors or improve quality, particularly of larger trials.21-26  119 
Central statistical monitoring of trial-related data, in combination with targeted site 120 
monitoring informed by statistical analysis, has been proposed as a more effective and efficient 121 
method of detecting material errors during the conduct of a trial and identifying opportunities for 122 
improvement prospectively.26-28 Regulatory authorities, particularly in the US and Europe, have 123 
now issued guidance documents that focus on a risk-based approach to monitoring, emphasizing 124 
“quality-by-design” concepts.29-31 The ICH-GCP Addendum includes similar language but the 125 
contradictory text in the original guideline remains.32 Widespread improvement seems unlikely 126 
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unless consistency is achieved in the guidance across all regulatory agencies, as well as in the 127 
approach used by regulatory inspectors and those who conduct trial monitoring. 128 
 129 
Safety Reporting 130 
A fundamental principle of clinical trials is the protection of clinical trial participants. 131 
However, the regulations and guidelines relating to safety reporting are unnecessarily complex 132 
and confusing, and frequently mis- or over-interpreted. Hence, important safety signals may get 133 
lost in the large volume of uninformative reports to regulatory authorities, ethics committees and 134 
investigators about adverse events.32 Recent EU and US legislation indicates that the nature and 135 
extent of adverse event reporting should be tailored to each trial protocol, and FDA guidance 136 
discourages excessive expedited adverse reaction reporting.9;33-35 However, this position is not 137 
well articulated in the ICH guidelines.36;37  138 
In early phase trials of new treatments, rigorous ascertainment of adverse events is 139 
necessary37 but, as knowledge of the safety profile of the treatment increases, the level of adverse 140 
event recording should decrease.24  However, there is a widespread misunderstanding that it is 141 
required to record all non-serious adverse events even in late-stage trials of treatments when this 142 
may be neither scientifically justified nor required by regulators. Attempting to record 143 
information on all adverse events in a large late-stage trial may distract attention from systematic 144 
ascertainment of those serious health outcomes that might matter clinically and in public health 145 
terms.24;38;39 Furthermore, clinicians view excessive reporting activities (including the frequent 146 
demand from sponsors to provide detailed narrative descriptions for common events not believed 147 
to be related to the study treatment) as burdensome and a disincentive to participation, which 148 
may result in fewer, smaller trials and less reliable evidence to guide patient care.18  149 
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Much of the emphasis in clinical trial guidelines is on expedited reporting of individual 150 
serious adverse events that are believed to be due to the study treatment (“reactions”) and not 151 
previously recognized as being caused by the treatment (“unexpected”).36 There is good evidence 152 
that focus on these requirements, combined with the subjective nature of the attribution of 153 
adverse effects to the study treatment, can lead to excessive uninformative reporting.32  Reports 154 
of such suspected unexpected serious adverse reactions (SUSARs) only have to be expedited if 155 
they have occurred among patients who were allocated the active study drug, so it is hard to draw 156 
meaningful conclusions about causality. Attribution of individual suspected adverse reactions to 157 
a treatment is only likely to be a reliable source of evidence about causation when both the effect 158 
is large and the particular adverse event would be expected to occur rarely in the type of patient 159 
being studied.40;41 In all other circumstances, adverse events need to be compared collectively 160 
between the randomized treatment arms to determine their relationship to treatment.34;42 In on-161 
going trials, such comparisons are best conducted by an unblinded Data Monitoring Committee 162 
(DMC), adequately firewalled from those responsible for conducting the study in order to protect 163 
the integrity of the trial results.43;44  164 
Despite introducing a new regulation that emphasised these points, a review conducted 165 
by the FDA’s Office of Hematology and Oncology Products found that there had been little 166 
improvement in the rate of expedited event reporting (with, if anything, an increase); only 14% 167 
of all such reports were considered to be appropriate, with the remainder not providing any 168 
useful information about the safety profile of the drug under investigation.32 Commercial 169 
sponsors have identified a lack of international harmonization, concerns about liability risks, and 170 
confusion about the rules for aggregated reporting as barriers to improving their adverse event 171 
reporting to regulatory authorities.45  172 
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Thus, although there have been advances in guidance about safety reporting issued by 173 
some regulatory authorities, modifications to ICH guidelines and the way that they are applied 174 
are clearly needed (see Figure 1). Changing guidance alone is unlikely to be sufficient; a more 175 
rational approach to safety monitoring will also need to be communicated widely and applied 176 
consistently by all involved – including trial sponsors, investigators, and regulatory authority 177 
reviewers, auditors and inspectors – so that there is a change in the mind-set. 178 
 179 
Promoting Innovation 180 
 There is intense interest in the implementation of innovative clinical trial models for 181 
cardiovascular research. For example, many therapies for acute coronary syndromes have been 182 
developed in randomized effectiveness trials comparing a new treatment versus the current 183 
standard treatment. Increasingly, randomized trials are using existing clinical infrastructure 184 
(including electronic healthcare records and registries)45-48 or collecting outcome information 185 
directly from patients (e.g., through smartphones and wearable sensors), without the involvement 186 
of a typical clinical research site. Overly cautious attitudes to innovation in trial design and the 187 
use of novel technologies may be the consequence of concerns about informed consent, privacy, 188 
information security, and data quality49 or uncertainty about whether such approaches will be 189 
accepted by regulators.50;51 However, it is important that clinical trial regulations (and the way in 190 
which they are interpreted and applied) keep pace with such innovation.52  191 
 192 
 193 
Transparency 194 
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 The public disclosure of clinical trial results ensures that the valuable contributions of 195 
study participants serve a meaningful purpose and advance the science and practice of medicine. 196 
Greater clinical trial transparency has been achieved through the use of clinical trial registries 197 
and requirements to report results.9 Although some trial funders and journal editors are keen to 198 
promote sharing of individual participant data,53-55 the potential benefits and challenges of doing 199 
so are the subject of ongoing debate.56-60 Access to patient-level data might offer unprecedented 200 
opportunities for confirmatory or novel analyses, design of future trials, and methodological 201 
research. However, it also carries potential risks (for example, data-derived subgroup analyses 202 
may yield unreliable conclusions and lead to inappropriate treatment decisions) and opportunity 203 
costs (diverting resources away from new trials of cardiovascular treatments), so moves in this 204 
direction should be considered carefully.61;62  205 
 206 
Education and Engagement 207 
 The fundamental importance of conducting well-designed randomized trials in 208 
cardiovascular disease is often under-appreciated. Ensuring that the public, patients, physicians 209 
(particularly in medical school curricula or early career), and policy makers are better informed 210 
in the value and key principles of clinical trials is a priority. Such initiatives should emphasize 211 
both the value of integrating clinical trials into routine practice63;64 and the need to facilitate the 212 
reliable evaluation of existing treatments, some of which may not be as effective65 or safe66;67 as 213 
they are thought to be. Similarly, informing patients about the ways in which they can participate 214 
in clinical trials, the measures that are taken to ensure that their data are secure, and the value this 215 
information provides to the quality of care should help to reduce their concerns. 216 
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 Patient advocacy groups can provide perspectives on disease or treatment burden and 217 
provide advice on the feasibility of specific aspects of a clinical trial, informing study design. 218 
Collaboration between patient groups and clinical trialists should be the norm rather than the 219 
exception. Likewise, patient perspectives should be included in the development of new 220 
guidelines and regulations, as has been done effectively in projects conducted by the FDA-221 
funded Clinical Trial Transformation Initiative but is notably absent from ICH processes.  222 
 223 
Ethics Review and Informed Consent 224 
The importance of ethics committees for the protection of the rights, safety and wellbeing 225 
of study participants is not a matter of debate. However, some of the other processes intended to 226 
achieve these protections are of questionable effectiveness or efficiency, especially for later 227 
phase studies of new drugs or pragmatic trials of well-known treatments. Informed consent is an 228 
essential component of recognizing patient autonomy and respect for a person’s right to make 229 
decisions about their participation in a clinical trial. However, in many cases, consent processes 230 
have become cumbersome, fail to provide study participants with the information necessary to 231 
allow them to make properly informed decisions, and are disproportionate to the level of risk 232 
involved. In particular, a streamlined approach should be adopted for pragmatic trials conducted 233 
in the setting of routine care. Such approaches are currently being considered in the proposed 234 
revisions to the Common Rule, which is the regulation that guides federally- supported human 235 
research in the US.68Although the EU Clinical Trials Regulation includes provisions for low-236 
(risk) intervention trials and cluster randomized trials,9 ICH-GCP does not currently address 237 
these issues.13  238 
 239 
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Conclusion 240 
 Cardiovascular therapeutics is built on a foundation of evidence-based practice created 241 
from decades of high-quality randomized trials. The ESC supports regulations and guidance that 242 
promote quality protections for clinical trial participants and meaningfully improve the reliability 243 
of the results of trials. However, regulations should be based on scientific principles, should be 244 
proportionate for the type of intervention and the extent of prior experience with it, and adaptable 245 
to the choice of trial design (including use of registry, electronic health record or sensor data). 246 
Regulations and guidance should also be internally consistent to avoid apparently conflicting 247 
requirements, which could lead to poor adoption of improved standards.  248 
The ESC has set out a number of priority initiatives to improve the quality of GCP 249 
guidelines for clinical trials and their appropriate implementation (Table 2). The ESC is sharing 250 
views generated by the workshop and has already contributed to the public consultation on the 251 
ICH-GCP addendum. The ESC is committed to partnering with patients, investigators, sponsors, 252 
and regulators to create a clinical trial environment fit for the 21st Century, one that provides 253 
appropriate protection for trial participants, encourages innovation, operates efficiently, and 254 
leads to better care and improved outcomes for patients with cardiovascular disease.  255 
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Figure Legend 257 
Figure 1: Key elements of Good Clinical Practice for randomized clinical trials 258 
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 Table 1. Examples of unclear, inconsistent and contradictory definitions within ICH-GCP (E6) 332 
Term ICH-GCP Definition Concern 
Adverse 
Event 
“Any untoward medical occurrence in a patient or clinical 
investigation subject administered a pharmaceutical product 
and which does not necessarily have a causal relationship 
with this treatment…” 
Implies that those not administered a pharmaceutical 
product (e.g. control group) cannot have adverse 
events 
Adverse 
Drug 
Reaction 
“…All noxious and unintended responses to a medicinal 
product related to any dose should be considered adverse 
drug reactions. The phrase responses to a medicinal product 
and an adverse event is at least a reasonable probability, ie., 
the relationship cannot be ruled out” 
The meaning of “is at least a reasonable probability” is 
very different from “cannot be ruled out” 
 
Serious 
Adverse 
Event or 
Serious 
Adverse 
“Any untoward medicinal occurrence that at any dose results 
in death, is life-threatening, requires inpatient hospitalization 
or prolongation of existing hospitalization, results in 
persistent or significant disability/incapacity, or is a 
congenital anomaly/birth defect” 
This is intended to define what is meant by “serious”.  
However, the text is confusing and can be interpreted 
as suggesting that Serious Adverse Event and Serious 
Adverse Reaction are synonymous. 
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Table 1. Examples of unclear, inconsistent and contradictory definitions within ICH-GCP (E6) (continued) 
 
19 
 
Term ICH-GCP Definition Concern 
Drug 
Reaction: 
Sponsor “An individual, company, institution, or organization which 
takes responsibility for the initiation, management, and/or 
financing of a clinical trial.” 
Not consistent with other regulations: 
US 21 CFR 312.3: “Sponsor means a person who takes 
responsibility for and initiates a clinical investigation. 
The sponsor may be an individual or pharmaceutical 
company, governmental agency, academic institution, 
private organization, or other organization.”69  
EU Clinical Trials Regulation: “Sponsor means an 
individual, company, institution or organisation which 
takes responsibility for the initiation for the 
management and for setting up the financing of the 
clinical trial.”9  
Note: EMA and FDA are both members of ICH 
Note:  These definitions are presented in the original ICH-GCP (E6) text and were left unaltered in the E6 (R2) Addendum.8;69  333 
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 Table 2. Priority Initiatives of the European Society of Cardiology to Improve the Feasibility and Quality of Cardiovascular 334 
Clinical Trials 335 
Priority Initiative Aim 
1. Support research on the utility of 
clinical trial activities 
Support approaches to evaluate specific clinical trial activities to determine their 
effectiveness, value, and impact on safety of trial participants and the reliability of the results. 
2. Make the case for improved 
regulation of clinical trials and 
participate in their development 
Contribute actively to the development of regulations and guidance that facilitate high quality 
clinical trials, working in collaboration with all relevant stakeholders (including academic 
trialists, patient advocates, regulators, non-commercial funders, and industry) 
3. Share best practice for 
translating regulatory requirements 
to practice 
Support collaborative efforts among academic trialists, patient advocates, regulators 
(including auditors and inspectors), non-commercial funders, and industry to establish a 
consensus on methods to translate regulatory guidance into modern clinical trials. 
4. Promote initiatives to reduce the 
over-interpretation and excessive 
application of reasonable regulatory 
requirements 
Promote initiatives that encourage interaction among academic trialists, patient advocates, 
regulators (including auditors and inspectors), non-commercial funders, and industry to 
identify and rectify examples of over-interpretation regulatory requirements (i.e., activities 
that are conducted out of conservative interpretation of regulations rather than actual 
requirements). 
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Table 2. Priority Initiatives of the European Society of Cardiology to Improve the Feasibility and Quality of Cardiovascular 
Clinical Trials (continued) 
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Priority Initiative Aim 
5. Promote widespread 
understanding of the role of clinical 
trials in high quality cardiovascular 
healthcare 
Provide mechanisms for educational initiatives targeting patients, practicing physicians, and 
policy makers on the importance of clinical trials for developing new therapies and for 
establishing the effectiveness of available therapies used in the setting of routine care. 
Through education, shift thinking towards a realization that, in the absence of such evidence, 
the most ethical approach is often to conduct a randomized trial. 
6. Encourage and facilitate effective 
engagement of patients and their 
advocates in the clinical trial 
enterprise 
Encourage patients and patient advocacy groups to become involved in decisions related to 
clinical trial design (e.g., ensure that trials are answering questions relevant to patients) 
and/or regulatory standards (e.g., regulations that protect patients while also enabling quality 
research to be conducted) 
 336 
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